- R3 Bio, backed by Tim Draper, is pitching brainless human clones for organs, despite public denials.
- The startup is advancing monkey 'organ sacks' in the Caribbean as a step toward human versions.
- Ethical dilemmas include using paid surrogates and redefining human life.
- Schloendorn is a biotech outsider, raising doubts about technical feasibility.
A biotechnology startup named R3 Bio, based in Richmond, California, has operated in stealth mode for years, but last week it emerged with a revelation that blends cutting-edge science with profound ethical dilemmas. The company, backed by billionaire Tim Draper and funds like Immortal Dragons, publicly announced its work on monkey 'organ sacks,' pitching it as an ethical alternative to animal testing. However, internal documents and confidential testimonies obtained by MIT Technology Review paint a bolder and more unsettling picture: founder John Schloendorn has been promoting the creation of brainless human clones to serve as backup bodies, a vision that could redefine the boundaries of life and death.
This news shows how cutting-edge biotech can challenge ethical and regulatory norms, with implications for medicine, insurance, and the definition of human life.
The Hidden Vision of R3 Bio
John Schloendorn, a PhD in biotechnology with a DIY lab in his Bay Area garage, has privately pitched a proposal that sounds like dystopian science fiction. It involves growing infant versions of humans with minimal brain structures, enough to sustain life but not consciousness, to provide replacement organs like kidneys or livers. In a presentation at the Abundance Longevity event, with tickets priced at $70,000, Schloendorn and co-founder Alice Gilman openly discussed full body replacement, including the possibility of transplanting brains into younger clones to extend lifespan. While R3 Bio categorically denies any intent to create human clones, internal agendas and documents show a detailed technical roadmap for 'body replacement cloning,' based on rare medical conditions like hydranencephaly, where children are born missing most of their brain.
Public Denials and Contradictions
On the same day R3 Bio introduced itself to the world in an interview with Wired, the company sent a sweeping disavowal to MIT Technology Review, stating that Schloendorn 'never made any statement regarding hypothetical non-sentient human clones' and that allegations of creating clones are 'categorically false.' Yet, this stance clashes with testimonies from attendees at private events, where personal cloning for spare organs was openly discussed. Alice Gilman, when pressed, admitted that the team 'reserves the right to hold hypothetical futuristic discussions,' an ambiguity suggesting the company keeps radical options open while advancing more publicly acceptable projects.
The startup is pitching brainless human clones for organs, a vision that redefines the boundaries of life and death.
Ethical and Regulatory Implications
R3 Bio's proposal touches sensitive nerves in bioethics, raising questions about the definition of human life and the limits of experimentation. Creating brainless clones might sidestep some concerns about consciousness, but it introduces risks of exploitation, especially in the initial phase where paid surrogate women are proposed. Moreover, the work with monkeys in the Caribbean, focused on 'organ sacks,' serves as an intermediate step that could pave the way for human versions, challenging global regulatory frameworks unprepared for these technologies. The scientific community has reacted with skepticism, noting that R3 Bio hasn't published significant research and Schloendorn is an outsider in biotechnology, increasing doubts about technical feasibility.
The Longevity Market Context
R3 Bio fits into an ecosystem of longevity startups backed by Silicon Valley venture capital, where figures like Peter Diamandis promote radical life extension. With investors like LongGame Ventures focused on eternal life, the company taps into a growing trend toward biotechnological solutions for aging. While there are no direct market data for crypto or finance in this case, Tim Draper's interest, known for bets on disruptive technology, suggests R3 Bio could attract more funding if it shows progress in its monkey projects, potentially valuing it in the hundreds of millions if it overcomes ethical and technical hurdles.
What to Watch Next
R3 Bio faces a path full of challenges: it needs to demonstrate the viability of its monkey 'organ sacks,' navigate a hostile regulatory landscape, and manage growing public attention that could trigger backlash. The coming months will be crucial to see if the company can advance its more modest plans while keeping its grander ambitions under wraps. For observers, this represents a case study in how biotech innovation can push the boundaries of what's ethically acceptable, with implications that could reshape entire industries, from medicine to life insurance.